Compare XPEL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPEL | SDGR |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | 2020 |
| Metric | XPEL | SDGR |
|---|---|---|
| Price | $53.40 | $17.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $24.90 |
| AVG Volume (30 Days) | 172.6K | ★ 882.6K |
| Earning Date | 02-25-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $461,460,000.00 | $256,951,000.00 |
| Revenue This Year | $16.20 | $23.69 |
| Revenue Next Year | $11.28 | $20.32 |
| P/E Ratio | $32.11 | ★ N/A |
| Revenue Growth | 10.29 | ★ 32.90 |
| 52 Week Low | $24.25 | $15.99 |
| 52 Week High | $55.84 | $28.47 |
| Indicator | XPEL | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 43.59 |
| Support Level | $51.93 | $16.07 |
| Resistance Level | $55.84 | $17.87 |
| Average True Range (ATR) | 1.89 | 0.72 |
| MACD | -0.24 | -0.15 |
| Stochastic Oscillator | 56.39 | 31.20 |
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.